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Regulatory T cells carry new ID
Regulatory T (T reg) cells have a new trademark and a new mode of action to 
go with it. While searching for a mysterious mechanism of T cell suppression, 
Deaglio et al. (page 1257) have also discovered a new and improved way to 
identify and purify T reg cells.
Some T reg cells suppress effector 
T cells by secreting inhibitory cytokines. But 
this suppression can continue even when 
cytokine activity is blocked, suggesting that 
other inhibitory mechanisms exist. Getting 
to the bottom of this mystery has been 
difficult due to the lack of cell surface 
markers that can be used to isolate pure 
populations of T reg cells for functional 
assays. CD25, a T reg cell surface receptor, 
is also expressed on activated T cells. 
Foxp3, on the other hand, is unique to T reg cells, but is hidden inside them.
While looking for alternate mechanisms of T reg–mediated immune 
suppression, the team considered two cell surface proteins—CD39 and CD73. 
CD39 is a surface-attached enzyme that jumpstarts the conversion of extracellular 
nucleotides such as ATP into AMP; AMP is further degraded by CD73 into 
adenosine—a known anti-inflammatory molecule that dampens T cell activation.
The team found that T reg cells from CD39-deficient mice were 50–60% 
less effective in inhibiting the proliferation of effector T cells in vitro and 
failed to prevent host T cells from rejecting skin grafts in transplantation 
models. CD39, which was previously not detected on T cells, was now found 
specifically on Foxp3+ T reg cells along with CD73. These surface proteins 
thus offer a simpler way to zero in on this hard-to-catch population. 
A mycobacterium that causes skin 
ulcers protects itself from the im-
mune system by suppressing den-
dritic cell (DC) activity, according 
Coutanceau et al. (page 1395).
In the initial stages of Myco-
bacterium ulcerans infection, the skin 
puckers up into nodules that brim 
with bacteria and inflammatory 
cells. But this primary immune 
response gradually loses steam. As 
disease progresses, the inflamma-
tory cells disappear and the nodules 
transform into festering ulcers. 
The bug seems to enforce immune 
suppression even outside the lesions 
as patients with ulcers have poor 
systemic cellular responses.
Coutanceau et al. found several 
structural similarities between my-
colactone—a lipid toxin produced 
by the bug—and known immune-
suppressive drugs, and postulated 
that the toxin might function as an 
immune modulator. They now 
find that mycolactone hinders the 
DCs that drive T cell activation. 
The toxin prevented skin-derived 
DCs from migrating to the draining 
lymph nodes and blood-derived 
DCs from acquiring their usual 
antigen-presenting and chemokine-
secreting functions. But why the 
toxin initially allows the primary 
immune response to occur and 
how it hobbles DCs after ulcers 
form are still unclear.
Other mycobacteria, such as the 
bug that causes tuberculosis, secrete 
related biologically active lipids. 
Some of them target macrophages 
and inhibit the production of inflam-
matory cytokines, not chemokines. 
The team is now investigating the 
structural and molecular basis of this 
difference in toxin function. 
Tumor-killing DCs
Cytotoxic T cells that are trained by 
dendritic cells (DCs) to recognize tumor 
antigens are thought to be the main artillery 
in an antitumor response. But Stary et al. 
now find that the teachers can also be 
dangerous. On page 1441, the authors report 
that DCs are also loaded with cytotoxic 
proteins and thus act as weapons of tumor 
mass destruction.
Skin tumors known as basal cell carci-
nomas shrink when smeared with Imiqui-
mod, a drug that activates Toll-like receptors 
(TLRs) 7 and 8 on DCs. Stary et al. had 
  previously found that mouse tumors that 
responded best to these drugs contained 
a large number of DCs. And as DCs recruit 
and activate T cells, the team assumed 
that the drug instigated the DCs to call in 
T cell troops.
The new study, however, shows that 
DCs that are activated by TLR 7/8 work 
by an entirely new mechanism. In human 
carcinomas treated with Imiquimod, two 
DC subsets—myeloid DCs (mDCs) and 
plasmacytoid DCs (pDCs)—vastly outnum-
bered T cells. The mDCs surrounded the 
tumor mass, whereas the pDCs infiltrated 
it. They both expressed several cytolytic 
molecules.
The mDCs, like natural killer cells, 
killed tumor cells that did not express MHC 
class I. The pDCs acted more like T cells 
and specifically destroyed antigen-positive 
cells in vitro. This varied target specificity 
implies that, together, these DCs kill all 
kinds of tumor cells. Imiquimod may thus 
be useful to treat tumors that don’t respond 
to T cell therapies. 
CD39-deficient T reg cells fail to 
suppress CD4+ T cells, resulting 
in skin graft rejection (squares).
Tumors (red) are attacked by surrounding mDCs 
(blue) and infiltrating pDCs (green).
Bacterial toxin cripples dendritic cells